Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer

Urology

Volumn 50, Issue 5, 1997, Pages 715-721

  Pannek, Jürgen ^b   Rittenhouse, Harry G ^b   Evans, Cindy L ^b   Finlay, Judith A ^b   Bruzek, Debra J ^b   Cox, Jennifer L ^b   Chan, Daniel W ^b   Subong, Eric N P ^b   Partin, Alan W ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SERUM; URINE;

AGED; FEMALE; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 0030721663     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00324-5     Document Type: Article

References (32)

1. Partin AW, and Oesterling JE: The clinical usefulness of prostate specific antigen: update 1994. J Urol 152: 1358-1368, 1994.
2. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, and Walsh PC: Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143: 747-752, 1990.
3. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, and Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
4. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, and Walsh PC: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150: 110-114, 1993.
5. Carter HB, Pearson JD, Metter EJ, Brant JL, Chan DW, Andres R, Fozard JL, and Walsh PC: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267: 2215-2220, 1992.
6. Seaman E, Whang M, Olsson CA, Katz A, Cooner WH, and Benson MC: PSA density (PSAD). Role in patient evaluation and management. Urol Clin North Am 20: 653-663, 1993.
7. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, and Lieber MM: Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 270: 860-864, 1993.
8. Stenman UH, Leinonen J, Alfthan H, Ranikko S, Tuhkanen K, and Alfthan O: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991.
9. McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, Lilja H, and Oesterling JE: Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 45: 729-744, 1995.
10. Sinha AA, Wilson MJ, and Gleason DF: Immunoelectron microscopic localization of prostate-specific antigen in human prostate by the protein A-gold complex. Cancer 60: 1288-1293, 1987.
11. Iwakiri J, Grandbois K, Wehner N, Graves HC, and Stamey T: An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands. J Urol 149: 783-786, 1993.
12. DeVere White RW, Myers FJ, Soares SE, Miller DG, and Soriano TF: Urinary prostate specific antigen levels: role in monitoring the response of prostate cancer to therapy. J Urol 147: 947-951, 1992.
13. Tremblay J, Frenette G, Tremblay RR, Dupont A, Thabet M, and Dubet JY: Excretion of three major prostatic secretory proteins in the urine of normal men and patients with benign prostatic hypertrophy or prostate cancer. Prostate 10: 235-243, 1987.
14. Breul J, Pickl U, and Hartung R: Prostate-specific antigen in urine. Eur Urol 26: 18-21, 1994.
15. Takayama TK, Vessella RL, Brawer MK, True LD, Noteboom J, and Lange PH: Urinary prostate specific antigen levels after radical prostatectomy. J Urol 151: 82-87, 1994.
16. Irani J, Millet C, Levillain P, Doré B, Begon F, and Aubert J: Serum-to-urinary prostate-specific antigen ratio: a potential means of distinguishing benign prostatic hyperplasia from prostate cancer. Eur Urol 29: 407-412, 1996.
17. Irani J, Millet C, Levillain P, Doré B, Begon F, and Aubert J: Serum-to-urinary prostate specific antigen ratio: its impact in distinguishing prostate cancer when serum prostate specific antigen level is 4 to 10 ng/ml. J Urol 157: 185-188, 1997.
18. Rittenhouse H, Tindall D, Klee G, Young C, Bostwick D, Saedi M, Grauer L, Mikolajczyk S, Finlay J, Kuus-Reichel K, et al: Characterization and evaluation of hK2: a potential prostate cancer marker, closely related to PSA, in Murphy GP, and Khoury S (Eds): Proceedings of the 1st International Consultation on Prostate Cancer. United Kingdom, Scientific Communication International, 1997, pp 133-140.
19. Partin AW, Criley SR, Subong EN, Zincke H, Walsh PC, and Oesterling JE: Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer. J Urol 155: 1336-1339, 1996.
20. Partin AW, and Carter HB: The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer. Urol Clin North Am 23: 531-540, 1996.
21. Partin AW, and Oesterling JE: The clinical usefulness of percent free-PSA. Urology 48 (suppl 6A): 1-3, 1996.
22. Wolff JM, Boeckmann W, Borchers H, Handt S, Reineke T, and Jakse G: Prostate-specific antigen: insufficient discrimination between benign prostatic hyperplasia and organ-confined prostate cancer. Urol Int 57: 170-175, 1996.
23. Graves HC, Sensabaugh GF, and Blake ET: Postcoital detection of a male-specific semen protein. Application for the investigation of rape. N Engl J Med 312: 338-343, 1985.
24. Kabalin JN, and Hornberger JC: Prostate-specific antigen is not excreted by human kidney or eliminated by routine hemodialysis. Urology 37: 308-310, 1991.
25. Filella X, Cases A, Molina R, Jo J, Bedini JL, Revert L, and Ballesta AM: Tumor markers in patients with chronic renal failure. Int J Biol Markers 5: 85-88, 1990.
26. Semjonow A, Hamm M, and Rathert P: Elimination kinetics of prostate-specific antigen serum and urine. Int J Biol Markers 9: 15-20, 1994.
27. Christensson A, Björk T, Nilsson O, Dahlén U, Matikainen MT, Crockett AT, Abrahamsson PA, and Lilja H: Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 150: 100-105, 1993.
28. Huber PR, Mattarelli G, Strittmatter B, van Steenbrugge GJ, Schmid HP, and Maurer A: In vivo and in vitro complex formation of prostate specific antigen with alpha 1-antichymotrypsin. Prostate 27: 166-175, 1995.
29. Woodrum D, French C, and Shamel LB: Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology 48 (suppl 6A): 33-39, 1996.
30. Young CYF, Andrews PE, and Tindall DJ: Expression and androgenic regulation of human prostate-specific kallikreins. J Androl 16: 97-99, 1995.
31. Darson MS, Pacelli A, Roche P, Rittenhouse HG, Wolfert RJ, Tindall DJ, and Bostwick DG: Human glandular kallikrein 2 (hK2) expression in prostate intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 49: 857-862, 1997.
32. Charlesworth MC, Young CY, Klee GG, Saedi MS, Mikolajczyk SD, Finlay JA, and Tindall DJ: Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels. Urology 49: 487-493, 1997.